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Abstract
Background: A systematic review of economic evaluations for lung cancer identified no economic models of the
UK setting based on disease natural history. We first sought to develop a new model of natural history for
population screening, then sought to explore the cost-effectiveness of multiple alternative potential programmes.
Methods: An individual patient model (ENaBL) was constructed in MS Excel® and calibrated against data from the
US National Lung Screening Trial. Costs were taken from the UK Lung Cancer Screening Trial and took the
perspective of the NHS and PSS. Simulants were current or former smokers aged between 55 and 80 years and so
at a higher risk of lung cancer relative to the general population. Subgroups were defined by further restricting age
and risk of lung cancer as predicted by patient self-questionnaire. Programme designs were single, triple, annual
and biennial arrangements of LDCT screens, thereby examining number and interval length. Forty-eight distinct
screening strategies were compared to the current practice of no screening. The primary outcome was incremental
cost-effectiveness of strategies (additional cost per QALY gained).
Results: LDCT screening is predicted to bring forward the stage distribution at diagnosis and reduce lung cancer
mortality, with decreases versus no screening ranging from 4.2 to 7.7% depending on screen frequency. Overall
healthcare costs are predicted to increase; treatment cost savings from earlier detection are outweighed by the costs
of over-diagnosis. Single-screen programmes for people 55–75 or 60–75 years with ≥ 3% predicted lung cancer risk
may be cost-effective at the £30,000 per QALY threshold (respective ICERs of £28,784 and £28,169 per QALY gained).
Annual and biennial screening programmes were not predicted to be cost-effective at any cost-effectiveness threshold.
Limitations: LDCT performance was unaffected by lung cancer type, stage or location and the impact of a national
screening programme of smoking behaviour was not included.
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Conclusion: Lung cancer screening may not be cost-effective at the threshold of £20,000 per QALY commonly used in
the UK but may be cost-effective at the higher threshold of £30,000 per QALY.
Keywords: Screening, Lung cancer, Diagnosis, Low-dose computed tomography, Natural history model, Cost-
effectiveness, QALY
Highlights
 ENaBL is a new economic model based on the
observed natural history of lung cancer and
calibrated to the US National lung screening trial.
 Additional advantages of evaluating multiple
populations and programme designs and adjusting
for lead time bias, length bias and over-diagnosis.
 LDCT lung screening is predicted to be effective in
reducing lung cancer mortality relative to no
screening in the range 4.2 to 7.7% depending on
screen frequency.
 Programmes are shown to increase diagnoses,
including over-diagnosis, and increase costs.
 LDCT screening is unlikely to be cost-effective at
the £20,000/QALY threshold, but a single screen of
60–75 year olds with ≥ 3% risk may be cost-effective
at £30,000/QALY.
Background
Lung cancer is a continuing major global public health
problem, and in the UK it is the leading cause of cancer
death (22%) [1]. In 2013, the UK had an above EU aver-
age death rate of 61.6 deaths per 100,000 [2]. Approxi-
mately 46,400 cases of lung cancer were diagnosed in
2014, representing 13% of the total number of cancer
cases [1]. The prognosis for long-term survival is poor.
One-year survival for adults in England and Wales in
2010–2011 was 32.1%. Cancer Research UK estimated 5-
and 10-year survival in 2010/2011 to be 9.5 and 4.9%,
respectively, in England and Wales [3].
Although the potential effectiveness of screening with
low-dose computed tomography (LDCT) has been dem-
onstrated in large trials like the National Lung Screening
Trial (NLST) in the USA, there is unresolved uncertainty
about cost-effectiveness [4]. A systematic review of exist-
ing economic evaluations of LDCT screening for lung
cancer has revealed markedly varied estimates. Few re-
views commented on the generalisability of their find-
ings, but certain assumptions regularly appeared as
significant in determining cost-effectiveness. Important
factors are the cost of a LDCT scan; the risk of lung can-
cer in the screened cohort (pertaining to prevalence but
also incidence for studies evaluating more than a single
screen); the effectiveness of LDCT screening in broad
terms, for example, achieving a stage shift without
significant over-diagnosis; extending lung cancer survival
beyond lead time; and reducing lung cancer mortality.
Two economic evaluations identified in the review were
conducted in the UK setting, based on the UK Lung
Cancer Screening Trial (UKLS) [5–7]. Both concluded
that LDCT screening could be cost-effective in the UK.
The latter of these evaluations included a comparison
with an economic evaluation based on the NLST,
highlighting the likely reasons why they found a disparity
[8, 9]. A third, recently published, UK evaluation was
based on findings from a community-based LDCT pilot
and a reconstruction of the UKLS model [10]. However,
these UK-based economic evaluations have not been
based on the highest quality evidence (although they
have produced somewhat consistent results in terms of
incremental QALYs compared with studies that are
based on high-quality evidence), have not tested multiple
screening programmes or populations and have not pre-
dicted the natural history of lung cancer in the absence
of screening. Outside the UK, three different natural
history models have been used to predict the cost-
effectiveness of LDCT screening. The Lung Cancer
Policy Model suggested that LDCT in the USA would
not be cost-effective [11]. The Cancer Risk Management
Model (renamed OncoSim) suggested that biennial
LDCT in the Canadian setting would be cost-effective
[12, 13]. Finally, the Microsimulation Screening Analysis
(MISCAN) lung model suggested that annual LDCT,
also in Canada, would be cost-effective [14]. We aimed,
therefore, to firstly develop a new model—able to simulate
occult disease—and secondly examine the cost-effectiveness
of multiple alternative potential screening programme for-
mats in the UK setting. This independent economic model,
called the Exeter NAtural history-Based economic model of
Lung cancer screening (ENaBL), takes our understanding of
screening in the UK setting further. It is parametrised using
high-quality evidence and adjusts for the positive biases as-
sociated with screen-detected cases, which may all inflate
the cost-effectiveness of screening. These are lead time bias,
which may artificially inflate screening effectiveness because
earlier diagnosis may not prolong survival in cases when
death is not delayed by earlier intervention; length bias,
which tends to increase in the proportion of slower progres-
sing less aggressive tumours, the detection of which may not
translate to greater survival; and over-diagnosis, because tu-
mours detected by screening that would not have clinically
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presented prior to death from other causes are frequently at-
tributed health benefits. ENaBL is able to mitigate for these
biases and also assesses multiple screening programmes
across alternative populations defined by age, gender and
risk score, enabling decision-makers to better evaluate differ-
ent policy/programme options. This paper and associated
monograph (for full methodological detail) conform to the
Consolidated Health Economic Evaluation Reporting Stan-
dards (CHEERS) [15, 16].
Methods
ENaBL is an individual patient simulation model devel-
oped using a discrete event simulation framework
whereby individual patients were sampled according to
baseline age, sex, presence of preclinical disease and pre-
dicted minimum risk of disease. This approach allows
transparent and flexible modelling of known patient and
disease heterogeneity and the time dependency of re-
lated events. Individual outcomes were simulated across
four alternative screening programmes defined by the
number of LDCT screening rounds and the time be-
tween rounds:
 (S) Single one-off screen shortly following entry
(UKLS protocol) [5]
 (T) Triple screen comprising a first screen shortly
following entry and subsequent screens at 12 and 24
months (NLST protocol) [4]
 (B) Biennial repeated screening from shortly after
entry then 24monthly from entry date but not
beyond 80th birthday
 (A), as described in (B) but screens are repeated
annually (USPSTF recommendations) [17].
The target population was current or former smokers
within the aged range 55 and 80 years with a higher risk
of lung cancer relative to the general population, in-
formed by a survey of an external advisory group.
Twelve population groups were defined by combinations
of further age restriction (55–80, 60–80, 55–75 and 60–
75 years) and alternative minimum threshold of pre-
dicted risk (≥ 3%, ≥ 4% and ≥ 5%) as calculated using the
Liverpool Lung Project tool version 2 [18, 19]. Individ-
uals meeting the criteria in the population group were
selected from a pool of 20,000 simulated individuals for
invitation into a screening strategy (costs and QALYs
were very stable after 15,000 simulations). Individuals
not meeting the criteria or failing to partake were
retained and received no screening (control). In total,
there were 48 intervention strategies.
The evaluation setting was the NHS in the UK, and
the cost perspective was the NHS and personal social
services (PSS). Only direct health effects on individuals
were included, no attempt has been made to model
societal impacts such as modified smoking behaviour
[20]. The primary outcome was the incremental cost-
effectiveness ratios between strategies, expressed in add-
itional cost per QALY gained (£, 2016/2017). Secondary
outcomes included screening programme sensitivity;
relative risk of lung cancer diagnosis, probability of early
diagnosis versus late, average lead time, number of lung
cancers diagnosed per 100,000 entrants (including inter-
val cancers), reduction in mortality due to lung cancer,
5-year lung cancer survival and change in age at diagno-
sis/death from lung cancer.
A lifetime time horizon was used in order to capture
all relevant costs and benefits, discounted at 3.5% per
year as per UK standard. Costs, QALYs and other out-
comes for each strategy were estimated using a decision
tree which identified appropriate simulated individuals
from the pool and assigned them to either one or more
screening interventions (if they meet all criteria and
wished to join the screening programme) or to no
screening.
In all strategies, individuals begin the simulation with-
out clinically diagnosed lung cancer, although they could
have preclinical (occult) lung cancer. A natural history
model was developed to generate disease incidence and
progression for individuals in the absence of screen
detection. In the event of a screening round, at a pre-
determined time since programme enrolment, partici-
pants were either diagnosed or cleared to continue in
the programme. There was no explicit modelling of
cancer progression after diagnosis: output costs and out-
comes are intended to be averaged across lung cancers
diagnosed in each stage. A diagram of possible patient
flow through the model is depicted in Fig. 1.
The rate of lung cancer detection by screening gives
rise to the differences in health benefit in each strategy
(earlier transition through ‘DETECTION’ in Fig 1). If de-
tected cancers were at an earlier stage than they would
have presented clinically, then the time to lung cancer
mortality was extended because the model relates sur-
vival to stage at diagnosis. If detection occurred earlier
but at the same cancer stage, then no survival benefit
was gained. This is a conservative construction included
to mitigate against positive biases such as lead time bias,
length bias and over-diagnosis [21].
Baseline risk of death was based on life tables which
were then adjusted for smoking and mortality rate due
to lung cancer [22–24]. A Bayesian Markov Chain Monte
Carlo analysis was conducted to calibrate mortality, preva-
lence, incidence and progression against the US NLST
findings and the incidence of lung cancer in England [1, 4,
25, 26]. A log-normal distribution was assumed for pre-
clinical incidence of lung cancer, and exponential distribu-
tions were assumed for the time to preclinical progression
(from Stage IA to Stage IB, from Stage IB to Stage IIA,
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etc.) and the time to clinical presentation (according to
the stage). It was assumed in the base case that there is no
heterogeneity between patients in the rate at which their
cancers progress or present, but this was tested in scenario
analyses.
The probability of an individual responding to an
initial questionnaire and the subsequent probability of
participation given they met the eligibility criteria
(46.5%) were estimated from the UKLS trial [5]. The
probability of LDCT correctly identifying those with
lung cancer (sensitivity) was 70.9%, estimated in the
calibration exercise, and the probability of correctly
identifying those without (specificity) was 62.4%, esti-
mated from the UKLS trial [5]. Baseline utility values
for smokers (in the absence of lung cancer or with pre-
clinical disease) were estimated controlling for sex and
age (0.753 for females and 0.782 for males for ages 75
to 84) [27], and stage-based utilities of smokers were
estimated from the health-related quality of life
(HRQoL) of lung cancer patients (stage II, 0.77; stage
III, 0.77; stage IV, 0.76) [27, 28]. It was assumed that
individuals with stage I cancers (mostly asymptomatic)
would have the same utility as smokers without lung
cancer. These utility values were used for men and
women in the model regardless of the current smoking
status (which was not modelled) and age. A small tem-
porary disutility was applied for lung cancer screening
itself (0.01 lasting for 2 weeks), and a more significant
disutility following a false-positive result (0.063 lasting
for 3 months) [29, 30].
Screening costs included the administration costs of
self-assessment surveys, scoring, follow-up invite/decline
of responder questionnaires, and the cost of LDCT ex-
amination(s) of programme joiners (this included a brief
Fig. 1 Model diagram for simulating individuals. LC, lung cancer. White boxes represent health states; grey boxes and arrows represent events.
An individual begins the simulation without clinically diagnosed lung cancer, because they do not have lung cancer or they have occult lung
cancer (health states on the left hand side). He/she is immediately at risk of incidental development of lung cancer, preclinical progression of the
occult tumour, detection or death from other causes. It is assumed that death from lung cancer is preceded by a diagnosis. Following detection,
the individual is again at risk of progression or death, now from either from lung cancer or other causes
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nurse assessment and the unit cost did not vary across
first or subsequent screens) [31, 32]. Resources utilisa-
tion rate for diagnosis, treatment and follow-up were
based on a retrospective 1-year cohort study of lung can-
cer patients at an English teaching hospital and were
matched to disease stage at diagnosis [33]. Costs were
applied for a maximum of 2 years post-diagnosis, with
second year costs adjusted from the index year accord-
ing to UK lung cancer resource patterns [34]. People
who received a false-negative screen were zero treatment
and follow-up cost until a true diagnosis of lung cancer,
and false positives consumed resources as per cases in
the UKLS trial [5]. End-of-life costs were included for
lung cancer deaths [35]. Costs were inflated when
needed to the adopted price year, 2016.
A summary of key input parameters are presented in
Table 1, and key assumptions around modelling approach
in Table 2; supplementary Tables S1 and S2 provide
unabridged details. ENaBL is publicly available, accessed
through the Open Research Exeter repository [37].
Commentary on the impact of these assumptions and
the outcome of testing alternative assumptions can be
found in Supplementary Table S1.
Results
Cost-effectiveness
There were four screening strategies that could be cost-
effective at different values of the cost-effectiveness
threshold, and these form the cost-effectiveness frontier
on the cost-effectiveness plane (Table 3). However, none
of the screening strategies would be considered cost-
effective versus no screening at a threshold of £20,000
per QALY. At a threshold of £30,000 per QALY, S-60-
75-3% (screening programme design ‘S’; participation
age range ‘60–75’ years; predicted lung cancer risk of
‘≥ 3%’) and S-55-75-3% would be cost-effective versus no
screening (ICERs £28,169 and £28,784 per QALY gained,
respectively).
All strategies were predicted to lead to health benefits,
ranging from 0.0003 to 0.0012 QALYs gained per person
in the higher risk target population, including non-
participating invitees. Health gains in programme partic-
ipants were more significant, ranging from 1.2 to 4.0% of
the population. Individuals participating in the S-60-75-
3% screening programme were predicted to gain an
average 0.054 life years (≈ 3 weeks) or 0.027 discounted
QALYs versus no screening, and mortality from lung
cancer was on average delayed 0.16 years (≈ 8 weeks).
Figure 2 illustrates incremental costs and QALYs for
each strategy on the cost-effectiveness plane. Figure 3
presents only those which form the cost-effectiveness
frontier, i.e., those that provide the maximum net
monetary benefit for at least one choice of the cost-
effectiveness threshold.
Secondary health outcomes
Screening increased the probability of lung cancer being
diagnosed in the early stages (I and II) versus later stages
(III and IV). The average odds ratios of early diagnosis
in programme designs were predicted to be 2.44 (S),
3.29 (T), 3.83 (B) and 5.62 (A). The forward-shift in
diagnosis in the single-screen programmes was most sig-
nificant for stage IA cancers, which were detected in
13% of participants versus 6% in no screening. Screening
also led to an increase in lung cancer lifetime diagnoses,
i.e., what would be considered over-diagnosis. The aver-
age relative risk of a lung cancer diagnosis was 1.11 (S),
1.15 (T), 1.18 (B) and 1.20 (A), with screen detections in
47.7% (S), 64.2% (T), 72.1% (B) and 80.6% (A) of lung
cancer diagnoses. Lung cancer diagnoses per 100,000
participants were on average 19,200 (S), 19,700 (T), 20,
300 (B) and 20,600 (A), compared to 17,200 for no
Table 1 Key input parameters of the model
Description Base case value Source
Number of smokers aged 55–80 13,000,000 Office of National Statistics [36] Health
survey for England [27]
Probability someone responds to the initial invite and returns the questionnaire 0.307 UKLS trial [6]
Probability someone joins screening programme given they are eligible 0.465 UKLS trial [6]
Sensitivity of low-dose CT test for lung cancer 0.709 UKLS trial [6]
Specificity of low-dose CT test for lung cancer 0.624 UKLS trial [6]
Utility of male smoker in the UK general population/occult lung cancer 0.7816 Health Survey for England [27]
Utility of female smoker in the UK general population/occult lung cancer 0.7531 Health Survey for England [27]
Disutility associated with a false-positive screen − 0.063 Mazzone et al. [30]
Disutility associated with anxiety of a screening event − 0.010 NELSON trial [29]
Duration of disutility from false-positive screen 3 months Assumption
Duration of disutility from screening anxiety 2 weeks Assumption
Cost of low-dose CT scan £98.80 NHS Reference costs 2015/2016 [31]
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screening. Interval cancers—those presenting between
screens—accounted for 3.9% (T), 11.8% (B) and 5.6% (A)
of diagnoses in multiple-screen programmes. There was
an average of 1.00 (S), 2.68 (T), 4.55 (B) and 8.03 (A)
LDCT screens per participant, with 0.32 (S), 0.93 (T),
1.60 (B) and 2.96 (A) false positive or indeterminate re-
sults per participant, respectively. Reduction in risk of
lung cancer mortality versus no screening ranged from
2.9 to 8.7% for participants. The average reduction in
mortality due to lung cancer was 4.2% (S), 4.4% (T),
5.2% (B) and 7.7% (A), and five-year survival was
predicted to be 20.3% (S), 26.2% (T), 29.1% (B) and
32.3% (A), compared to 4.7% for no screening. Lung
cancer deaths per 100,000 participants were on average
15,200 (S), 15,100 (T), 15,000 (B) and 14,600 (A), com-
pared to 15,800 for no screening. Detailed clinical out-
comes for screening strategies on the cost-effectiveness
frontier are presented in Table 4.
Resources and costs
The costs per participant for LDCT screening and sub-
sequent lung cancer care increased in accordance with
the frequency of screening, up to £690 and £1118, re-
spectively, as incrementally more diagnoses are made
and more resources are consumed. The cost of end-of-
life care decreased slightly as survival increased with
frequency of screening, but if there are savings in the
cost of treatment from earlier detection (not explicitly
explored) then these are outweighed by the additional
cost of over-diagnoses. Taking a relevant population of
13 million smokers aged 55 to 80 years old, the pro-
grammes are predicted to lead to population lifetime
cost increases of £299 million to £634 million. The
direct marginal cost of running a screening programme
makes up less than half of this increased cost, with the
rest being due to lung cancer care.
Additional analyses
A secondary analysis of cost-effectiveness when varying
screening frequency in fixed populations found that an-
nual and biennial screening were dominated by triple
screening in all populations, which always gave the most
QALYs. Optimisation analysis of age limits and pre-
dicted risk, using net monetary benefit (willingness-to-
pay £20,000 per QALY), identified a tentative target
population, for the single-screen design, of age range 64
to 67 years and a minimum risk threshold of ≥ 2%,
producing an ICER versus no screening of £13,361 per
QALY gained.
Uncertainty
Internal model validity was tested with univariate, sce-
nario and probabilistic analyses. Univariate sensitivity
Table 3 Base case results of screening strategies forming the cost-effectiveness frontier (per person)
Strategy Change in 5-year
lung cancer survival
Costs QALYs ICER (versus current
/no screening)
ICER (versus previous)
No screening £1103 8.50215
S-60-75-3%a + 16.1% £1126 8.50297 £28,169 £28,169
S-55-75-3% + 16.4% £1129 8.50306 £28,784 £35,453
S-55-80-3% + 16.1% £1135 8.50319 £30,821 £44,087
T-55-80-3% + 21.0% £1151 8.50337 £40,034 £95,292
aIn a fully incremental analysis, only S-60-75-3% would be cost-effective at a threshold of £30,000 per QALY gained. ICER incremental cost-effectiveness ratio, QALY
quality-adjusted life year, S single one-off screen design, T triple-screen design. Strategy nomenclature: X-XX-XX-X% = screening programme design type-
minimum entry age-maximum entry age-minimum lung cancer risk threshold
Table 2 Key assumptions of the model
Changes in smoking behaviour are not modelled.
Programme uptake will be similar in real life to in the UKLS trial.
There is full concordance with screening programme (i.e. no missed
appointments)
Health-related quality of life similar for preclinical and diagnosed lung
cancer (stratified by stage).
Health-related quality of life similar for clinically presenting and screen-
detected lung cancer of the same stage.
Health-related quality of life for diagnosed lung cancer is constant until
death.
Natural history of lung cancers is similar across all included individuals.
Lung cancers progress through stages in numerical order without
skipping any stages.
Sensitivity of LDCT is independent of patient and tumour characteristics.
Lung cancer mortality: screening cannot be less effective than no
screening.
Mortality from preclinical lung cancer assumed to be negligible.
Lung cancer incidence in participating population similar to incidence in
general smoking (current and former) population.
Survival in participating population similar to survival in general
population (stratified by stage).
Incidental findings not modelled.
True-positive results lead to immediate diagnosis and treatment.
False-positive and indeterminate results are treated equivalently.
Non-attendance of screening was not explicitly modelled
Additional cancers caused by radiation exposure not modelled.
Risk prediction is dependent only on prevalence of occult lung cancer
or short-term incidence (within 3 years).
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analysis (supplementary Figure S1) found four of the
five most influential input parameters were related to
the natural history for smokers, the other was the cost
of LDCT. The specificity of screening appears to be
more influential than the sensitivity, but in both cases
improved diagnostic performance leads to improved
cost-effectiveness. Likewise, the performance level of
risk prediction positively affects cost-effectiveness. In a
scenario analysis, of the 17 alternatives explored, cost-
effectiveness at £20,000 per QALY was achieved only
when false-positive and indeterminate results were
attributed nil effect on HRQoL, or when discounting of
future costs and benefits was removed. Probabilistic
sensitivity analysis (PSA) estimates compared well with
deterministic estimates although the cost-effectiveness
frontier moved to include only S-60-80-3% and S-55-
75-3%, with the multiple screening strategy T-55-80-3%
displaced. Cost-effectiveness acceptability curves in the
PSA analysis showed that no screening had the highest
probability of being cost-effective for thresholds up to
£50,000 per QALY, although S-60-75-3% and S-60-80-
3% are expected to be cost-effective at thresholds below
£50,000 per QALY [38].
Discussion
The lung cancer screening programmes simulated here
are predicted to lead to health benefits for participants
compared to no screening. We estimate a reduction in
Fig. 2 Cost-effectiveness plane for base case per person results across all strategies. QALY, quality-adjusted life year
Fig. 3 Cost-effectiveness plane for base case per person results of frontier strategies. QALY, quality-adjusted life year; S, single one-off screen
design; T, triple-screen design. Strategy nomenclature: X-XX-XX-X% = screening programme design type-minimum entry age-maximum entry
age-minimum lung cancer risk threshold
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mortality from lung cancer ranging from 4.2 to 7.7%, de-
pending on screening frequency, but find increased lung
cancer diagnoses (including indolent cases), and in-
creased lung cancer costs. In the base case analysis, it is
predicted that when using a cost-effectiveness threshold
of £20,000 per QALY, none of the programmes would
be considered a cost-effective use of limited NHS re-
sources versus the current UK strategy of no screening.
At a higher cost-effectiveness threshold of £30,000 per
QALY a single-screen offered to people aged 60 to 75
years with a predicted risk of lung cancer of at least 3%
could be cost-effective. The PSA showed that when the
threshold increased from £20,000 to £30,000 per QALY,
the probability of no screening being the most cost-
effective option decreased from 70 to 50%. However, at
£30,000 per QALY, there are a number of LDCT screen-
ing strategies which could potentially be cost-effective,
and therefore the probability of any one strategy being
optimally cost-effective is low. Furthermore, simulation
of this complexity is inherently uncertain.
One-way sensitivity analyses showed that a 10% vari-
ation in any single parameter is unlikely to result in
LDCT screening being cost-effective at £20,000 per
QALY and that ICERs were most sensitive to the
Table 4 Detailed clinical outcomes and costs, for participants of strategies on the cost-effectiveness frontier
Screening programme strategy No screening S-60-75-3% S-55-75-3% S-55-80-3% T-55-80-3%
Mean outcomes per participant (versus no screening)
Number of screens 1.00 1.00 1.00 2.70
Number of false positives 0.33 0.33 0.33 0.95
Lead time (years) 0.2995 0.2992 0.2952 0.3946
Life years gained (years) 0.0537 0.0568 0.0524 0.0762
QALYs 0.0008 0.0009 0.001 0.0012
Change in lung cancer mortality − 0.80% − 0.45% − 0.43% − 0.64%
Change in 5-year lung cancer survival + 16.1% + 16.4% + 16.1% + 21.0%
Change in survival with lung cancer (years) + 1.87 + 1.89 + 1.85 + 2.44
Change in age at lung cancer diagnosis (years) − 1.7 − 1.69 − 1.62 − 2.03
Change in age at death from any cause (years) + 0.05 + 0.06 + 0.05 + 0.08
Change in age at death from lung cancer (years) + 0.16 + 0.2 + 0.23 + 0.41
Outcomes per 100,000 participants
Proportion of diagnoses arising from screening 44.4% 44.3% 47.1% 62.5%
Number of screen-detected cases 1710 1785 2335 3185
Number of interval cancers 0 0 0 215
Additional lung cancer diagnoses 295 300 450 590
Lung cancer deaths averted 170 100 120 180
Life years gained 5367 5677 5242 7617
Costs for each participant (£, versus no screening)
LDCT screening 104 104 104 275
Lung cancer care 1458 1445 1469 1724
End-of-life 534 530 515 505
Total 2097 2080 2088 2504
Population of 13 million smokers aged 55–80 years
(lifetime costs, £ million)
Screening administration 0 80.16 110.97 118.66 118.66
LDCT screening 0 41.42 43.53 54.06 142.48
Lung cancer care 9355 9540 9547 9610 9742
End-of-life 4979 4972 4971 4970 4965
Total 14,334 14,633 14,673 14,753 14,968
Additional vs no screening 299.1 338.8 418.5 634.2
LDCT low-dose computed tomography, QALY quality-adjusted life year, S single one-off screen design, T triple-screen design. Strategy nomenclature: X-XX-XX-X%
= screening programme design type-minimum entry age-maximum entry age-minimum lung cancer risk threshold
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modelling of the natural history of lung cancer, the cost
of treating lung cancer and the cost of LDCT scans.
Scenario analyses demonstrated that the impact of false-
positive and indeterminate screening results on HRQoL
was important in determining cost-effectiveness, as was
the discount rate of future costs and benefits. While
anxiety and distress from screening results may be stud-
ied, as well as potentially affected by a variety of inter-
ventions, the adjustment to decrease the value of future
costs and benefits is applied broadly and similarly across
health technology assessment. Since the health effects of
lung cancer screening do not lag significantly behind the
costs, because survival is generally poor and benefits are
accrued relatively soon, there is no good case to deviate
from standard approaches [39].
We believe ENaBL is the first economic evaluation of
lung cancer screening to include a risk prediction com-
ponent with a variable threshold, although risk proxies
in the form of smoking histories have been used [40].
Further, this is the first UK-based model to adjust for
over-diagnosis, the phenomenon in screening pro-
grammes whereby nodules/tumours which would not
have been clinically significant during the patient’s life
are detected. This has been estimated to be 18% of
screen-detected lung cancers relative to chest X-ray
screening or 31% relative to no screening [41]. The
model results are driven substantially by the natural his-
tory model, which allows for the evaluation of multiple
hypothetical screening programmes which have not been
evaluated in clinical trials. The natural history compo-
nent is based on high-quality evidence from the large US
NLST RCT and UK national sources [1, 25]. Previous
UK-based models have been based on ELCAP, a much
smaller study [42]. This publicly available model predicts
an impact on lung cancer mortality of − 4.2 to − 7.7%
depending on the frequency of screening. This is in good
agreement with the estimated 5% reduction in lung can-
cer mortality estimated by our associated network meta-
analysis, providing some confidence in this modelled
endpoint [15]. By using the discrete event simulation
framework, there has been no need to artificially restrict
the model states or distributions for event times or to
consider a homogeneous cohort. There were few sensi-
tivity analyses in which lung cancer screening became
cost-effective at a threshold of £20,000 per QALY, which
suggests some amount of robustness in the findings, al-
though a number of key assumptions are not explored
(e.g. no change in smoking behaviour, and impact of in-
cidental findings). The model does not take the impact
of screening on mortality as an input but produces it as
an output resulting from the natural history model and
the programme design. This helps internal validity and
provides flexibility, so if additional mortality benefit
needs to be incorporated, if it is demonstrated in future
trials, then new assumptions and parameters will need
to be introduced. Indeed, the current model predicts
that the cost-effectiveness of screening is closely linked
to the relative risk of lung cancer mortality: a relative
risk of 0.935 in single-screen individuals aged 60–75
years with ≥ 3% risk of lung cancer would become cost-
effective at £20,000 per QALY (although this is based on
extrapolation and is therefore subject to significant
uncertainty).
The costs of lung cancer have been estimated from a
single English teaching hospital and therefore may not
be fully generalisable to the whole of the UK at present,
due to possible variation in clinical practice or use of
technologies, and any significant changes in drug acqui-
sition prices. This economic evaluation does not include
a cost to identify target individuals from GP records,
which would be non-zero but nominal. It takes the invi-
tation response rate observed in UKLS, but a sample of
individuals selected for trial may be biassed towards
participation [5]. The economic evaluation currently as-
sumes that the stage of lung cancer is relevant only to
survival, it does not consider the relationship between
the stage of lung cancer and the performance of LDCT,
relevant because the identification of small nodules in
early stage lung cancer may be more challenging [43].
Also, the model does not consider whether lung cancer
type or location affects performance of screening, costs
or survival.
Estimates of cost-effectiveness of screening across other
health conditions are varied and, as in this case, are often
complex and sensitive. Research for the UK National
Screening Committee found that strategies for both bowel
cancer (one-off faecal immunochemical test) and cervical
cancer (primary HPV screen) are more effective and less
costly than no screening [44, 45]. However, screening for
ovarian cancer (multimodal) is either highly cost-effective
versus no screening or dominated by no screening,
depending on the chosen time horizon [46].
Conclusion
Evidence from ENaBL suggests that LDCT screening for
lung cancer may not be cost-effective, depending on the
cost-effectiveness threshold used [47]. Thresholds of
£20,000 to £30,000 per QALY are commonly used in the
UK, and screening is estimated to be cost-effective with
the higher threshold, but not with the lower. This evalu-
ation suggests that screening would result in a reduction
in lung cancer mortality, but also an increase in lung
cancer diagnoses, and additional costs. One screening
strategy that was investigated provided a ratio of add-
itional costs to benefits that was at the upper limit of
what would conventionally be considered cost-effective
in the UK, while other screening strategies were outside
the normal range of cost-effectiveness. Screening
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strategies with annual or biennial scans are not expected
to be cost-effective regardless of the amount one is will-
ing to pay for benefits. Early results from the NELSON
trial appear to support the positive mortality benefits
demonstrated by the NLST but may also show our find-
ing to be conservative [48]. An extension of this eco-
nomic evaluation—which considers multiple programme
designs and adjusts for over-diagnosis bias—to include
the full findings of the NELSON trial would significantly
enhance the evidence base for decision-makers wishing
to consider the cost-effectiveness of lung cancer screen-
ing in the UK.
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